Prosecution Insights
Last updated: November 20, 2026

James J Graber, USPTO Patent Examiner

Listed by the USPTO as GRABER, JAMES J

Tech Center 1600 • Art Units: 1631 1633

This examiner grants 46% of resolved cases

Analysis

GRABER, JAMES J is assigned to tech center 1600 and art unit 1631. The profile includes 200 resolved cases, with an allowance rate of 46.5% and a median of 1389 days to allowance. Interview lift is 57.6%, higher than the overall allowance measure.

The listed companies are Duke University, St. Jude Children's Research Hospital Inc., and Janssen Pharmaceuticals Inc. The listed firms are POLSINELLI and DUKE UNIVERSITY, THOMAS | HORSTEMEYER, LLP, and AMSTER, ROTHSTEIN & EBENSTEIN LLP. The interview result supports considering interviews as a meaningful tactic, but the allowance result calls for careful claim and evidence strategy. The median duration indicates that applicants should plan for extended prosecution and preserve continuation options.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

46.5%
Allow Rate
-13.5% vs TC avg
250
Total Applications
+57.6%
Interview Lift
1389
Avg Prosecution Days
Based on 200 resolved cases, 2023–2026

Rejection Statute Breakdown

5.2%
§101 Eligibility
16.5%
§102 Novelty
35.5%
§103 Obviousness
29.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18952458 COMPOSITIONS AND METHODS FOR IMPEDING TRANSCRIPTION OF EXPANDED MICROSATELLITE REPEATS Non-Final OA University of Florida Research Foundation, Incorporated
18558859 UNIVERSAL RETARGETING OF ONCOLYTIC HSV Non-Final OA Janssen Biotech, Inc.
18721743 NON-HUMAN ANIMALS COMPRISING HUMANIZED ACE2 AND TMPRSS LOCI Non-Final OA Regeneron Pharmaceuticals, Inc.
18953275 METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF TUMORS Non-Final OA THE GENERAL HOSPITAL CORPORATION
18367392 NEURONAL CELL CULTURES AS COMPUTE SUBSTRATES Final Rejection MICROSOFT TECHNOLOGY LICENSING, LLC
18289881 3D HUMAN DISTAL LUNG ORGANOIDS CONTAINING EPITHELIAL, IMMUNE AND MESENCHYMAL COMPONENTS Final Rejection The Board of Trustees of the Leland Stanford Junior University
18568091 METHODS FOR ENGINEERING AND USE OF CILIATED ORGANOIDS HAVING NATIVE-LIKE, APICAL-OUT POLARITY Non-Final OA Carnegie Mellon University
18294033 CULTURED ADIPOSE TISSUE Non-Final OA Trustees of Tufts College
18248193 PRODUCTION OF MEGAKARYOCYTES AND PLATELETS IN A CO-CULTURE SYSTEM Final Rejection BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18853458 CHIMERIC ANTIGEN RECEPTOR T CELLS AND METHODS OF USE THEREOF Non-Final OA The Regents of the University of Colorado, A Body Corporate
18547332 Compositions For and Methods of Improving Gene Therapy Non-Final OA Duke University
17637760 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH Final Rejection DUKE UNIVERSITY
18840303 MULTIPLEXED REPRESSION OF IMMUNOSUPPRESSIVE GENES Non-Final OA Yale University
18707756 STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS Non-Final OA VERTEX PHARMACEUTICALS INCORPORATED
17783040 Method for Preparing CD7-Negative, CD3-Positive T Cells Non-Final OA ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
18704322 METHOD FOR PRODUCING ORGANISM, AND METHOD FOR PROMOTING DIFFERENTIATION OF HUMAN ADIPOSE-DERIVED STEM CELLS INTO VASCULAR ENDOTHELIAL CELLS Final Rejection KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
18517402 METHOD FOR PREPARING BROWN ADIPOCYTE Final Rejection KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
18682797 GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY TO REDUCE INSTANT BLOOD MEDIATED INFLAMMATORY REACTIONS Non-Final OA Sana Biotechnology, Inc.
17640711 GENE EDITING FOR VIRAL INFECTIONS Final Rejection THEMBA INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner James J Graber's allowance rate?

46.5% of resolved applications examined by James J Graber were allowed (200 resolved cases), compared with 28.0% across Art Unit 1631 over the last five years.

Does an interview help with examiner James J Graber?

This examiner's interview lift is +57.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner James J Graber take to allow a patent?

Applications allowed by James J Graber took 1,389 days on average from filing to allowance.

Which art unit does examiner James J Graber work in?

James J Graber examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month